ANNA REYES-CRAWHORN: Open Payments
NPI 1154978732 · JEFFERSONVILLE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$929 in 40 payments from 14 companies in 2025. Trend: 2023 $364 · 2024 $421 · 2025 $929
Food & beverage: $830Education: $99
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $210 |
| Teva Pharmaceuticals USA, Inc. | 4 | $168 |
| Vanda Pharmaceuticals Inc. | 5 | $119 |
| ABBVIE INC. | 4 | $85 |
| Otsuka America Pharmaceutical, Inc. | 3 | $72 |
| Supernus Pharmaceuticals, Inc. | 3 | $53 |
| Alkermes, Inc. | 2 | $52 |
| Neurocrine BioSciences, Inc. | 2 | $44 |
| Almatica Pharma LLC | 1 | $26 |
| Lundbeck LLC | 1 | $26 |
Products named: CAPLYTA, VRAYLAR, REXULTI, FANAPT, HETLIOZ, Qelbree, ARISTADA, AUSTEDO XR.
Industry payments across IN — which companies pay providers there.
